S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
S&P 500   3,829.34
DOW   31,402.01
QQQ   312.83
Log in

Capricor Therapeutics Stock Forecast, Price & News

-0.51 (-7.67 %)
(As of 02/25/2021 12:00 AM ET)
Today's Range
Now: $6.14
50-Day Range
MA: $6.23
52-Week Range
Now: $6.14
Volume511,289 shs
Average Volume1.33 million shs
Market Capitalization$125.55 million
P/E RatioN/A
Dividend YieldN/A
Capricor Therapeutics, Inc. (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor's lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy. Capricor has also established itself as one of the leading companies investigating the field of extracellular vesicles and is exploring the potential of CAP-2003, a cell-free, exosome-based candidate, to treat a variety of disorders.
Capricor Therapeutics logo


See More Headlines

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Current SymbolNASDAQ:CAPR
Year FoundedN/A



Sales & Book Value

Annual Sales$1 million
Book Value$1.31 per share


Net Income$-7,640,000.00
Net Margins-2,304.84%


Market Cap$125.55 million
Next Earnings Date3/17/2021 (Estimated)
OptionableNot Optionable


Overall MarketRank

1.16 out of 5 stars

Medical Sector

873rd out of 1,957 stocks

Pharmaceutical Preparations Industry

425th out of 771 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
-0.51 (-7.67 %)
(As of 02/25/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive CAPR News and Ratings via Email

Sign-up to receive the latest news and ratings for CAPR and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Capricor Therapeutics (NASDAQ:CAPR) Frequently Asked Questions

Is Capricor Therapeutics a buy right now?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Capricor Therapeutics in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Capricor Therapeutics stock.
View analyst ratings for Capricor Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Capricor Therapeutics?

Wall Street analysts have given Capricor Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Capricor Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Capricor Therapeutics' next earnings date?

Capricor Therapeutics is scheduled to release its next quarterly earnings announcement on Wednesday, March 17th 2021.
View our earnings forecast for Capricor Therapeutics

How were Capricor Therapeutics' earnings last quarter?

Capricor Therapeutics Inc (NASDAQ:CAPR) posted its earnings results on Thursday, November, 12th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by $0.02. The biotechnology company had revenue of $0.02 million for the quarter. Capricor Therapeutics had a negative trailing twelve-month return on equity of 55.79% and a negative net margin of 2,304.84%.
View Capricor Therapeutics' earnings history

How has Capricor Therapeutics' stock price been impacted by COVID-19 (Coronavirus)?

Capricor Therapeutics' stock was trading at $1.0050 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, CAPR stock has increased by 510.9% and is now trading at $6.14.
View which stocks have been most impacted by COVID-19

What price target have analysts set for CAPR?

2 brokers have issued 1-year price objectives for Capricor Therapeutics' stock. Their forecasts range from $9.00 to $12.00. On average, they anticipate Capricor Therapeutics' share price to reach $10.50 in the next year. This suggests a possible upside of 71.0% from the stock's current price.
View analysts' price targets for Capricor Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Capricor Therapeutics' key executives?

Capricor Therapeutics' management team includes the following people:
  • Frank I. Litvack M.D., Independent Executive Chairman of the Board (Age 59)
  • Linda Marban Ph.D., President, Chief Executive Officer, Director (Age 51)
  • Anthony Bergmann, Chief Financial Officer, Principal Accounting Officer (Age 32)
  • Karen G. Krasney J.D., Executive Vice President, General Counsel (Age 62)
  • Thomas Lyle Copmann Ph.D., Vice President - Regulatory Affairs and Drug Development (Age 61)
  • Houman Hemmati M.D., Ph.D., Vice President - Medical & Clinical Development, New Therapies
  • Luis Rodriguez-Borlado Ph.D., Vice President - Regenerative Therapies
  • Rachel Smith Ph.D., Vice President - Research & Development (Age 36)
  • Deborah Ascheim M.D., Chief Medical Officer
  • Joshua A. Kazam, Director (Age 40)

Who are some of Capricor Therapeutics' key competitors?

What other stocks do shareholders of Capricor Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Capricor Therapeutics investors own include Marinus Pharmaceuticals (MRNS), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Vaxart (VXRT), Inovio Pharmaceuticals (INO), Trevena (TRVN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), OPKO Health (OPK) and Advanced Micro Devices (AMD).

What is Capricor Therapeutics' stock symbol?

Capricor Therapeutics trades on the NASDAQ under the ticker symbol "CAPR."

Who are Capricor Therapeutics' major shareholders?

Capricor Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (1.68%), Northern Trust Corp (0.67%), Bank of New York Mellon Corp (0.44%) and GSA Capital Partners LLP (0.39%).
View institutional ownership trends for Capricor Therapeutics

Which major investors are selling Capricor Therapeutics stock?

CAPR stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp.
View insider buying and selling activity for Capricor Therapeutics
or view top insider-selling stocks.

Which major investors are buying Capricor Therapeutics stock?

CAPR stock was bought by a variety of institutional investors in the last quarter, including GSA Capital Partners LLP, Bank of New York Mellon Corp, and BlackRock Inc..
View insider buying and selling activity for Capricor Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Capricor Therapeutics?

Shares of CAPR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Capricor Therapeutics' stock price today?

One share of CAPR stock can currently be purchased for approximately $6.14.

How much money does Capricor Therapeutics make?

Capricor Therapeutics has a market capitalization of $125.55 million and generates $1 million in revenue each year.

What is Capricor Therapeutics' official website?

The official website for Capricor Therapeutics is www.capricor.com.

Where are Capricor Therapeutics' headquarters?

Capricor Therapeutics is headquartered at 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211.

How can I contact Capricor Therapeutics?

Capricor Therapeutics' mailing address is 8840 WILSHIRE BLVD 2ND FLOOR, BEVERLY HILLS CA, 90211. The biotechnology company can be reached via phone at 310-358-3200 or via email at [email protected]

This page was last updated on 2/26/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.